Clinical Trial Detail

NCT ID NCT02488408
Title Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements No
Sponsors BerGenBio AS
Indications

acute myeloid leukemia

Therapies

Cytarabine

Bemcentinib

Age Groups: adult

No variant requirements are available.